United Therptcs Free of FREEDOM

United Therapeutics Corporation (UTHR - Analyst Report), a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases. It offers products primarily in three therapeutic areas, including cardiovascular, cancer and infectious diseases.

We were rightfully bearish on United heading into the FREEDOM-C data earlier in the week. The trial failed, as we predicted it would. Oral Remodulin seems unlikely before 2012. However, thanks to a quick deal with Eli Lilly & Co. (LLY - Analyst Report), United will move into the oral PAH [pulmonary arterial hypertension] market sooner than expected with Cialis.

Therefore, with the biggest hiccup now past, and upside potentially coming next year, United Therapeutics no longer looks like a Sell. Our rating is now Hold.

Read the full analyst report on UTHR

Read the full analyst report on LLY